New study aims to predict dangerous side effects of cancer immunotherapy
NCT ID NCT06377059
First seen Mar 15, 2026 · Last updated May 07, 2026 · Updated 6 times
Summary
This study watches 100 blood cancer patients closely after they receive CAR T-cell or bispecific antibody therapy. Researchers track vital signs and immune markers to find early warning signs of cytokine release syndrome and other complications. The goal is to learn who needs extra monitoring and to better understand how the body reacts to these treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rigshospitalet
RECRUITINGCopenhagen O, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.